Filing Flows › Health Care › Crescent Biopharma (CBIO)
Crescent Biopharma (CBIO) earnings and revenue breakdown
Latest: Q1 2026 · 10-Q filed Apr 29, 2026 · Crescent Biopharma (CBIO) Q1 2026 earnings results →
Crescent Biopharma made $1.0M in Q1 2026. Operating margin n/m, net loss $23.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Apr 29, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.0M in Q1 2026.
Operating costs exceeded revenue by $24.7M, an operating margin of -2380.1%. The quarter ended with a net loss of $23.3M.
Operating cash flow was −$8.9M. Non-cash charges added back $64K of depreciation and $4.1M of share-based compensation. Working capital and other items added $10.2M. Capital expenditures of $147K exceeded it, leaving free cash flow of −$9.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2026 | 10-Q | Apr 29, 2026 | $1.0M | — | n/m | −$23.3M | −$8.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Crescent Biopharma
We were incorporated under the laws of the State of Delaware in 2003. Our company, formerly known as GlycoMimetics, Inc., is a biotechnology company that is the result of a reverse recapitalization transaction with a private company named Crescent Biopharma, Inc. (“Pre-Merger Crescent”). Prior to the reverse recapitalization transaction, Pre-Merger Crescent was established and incorporated under the laws of the state of Delaware on September 19, 2024. On June 16, 2025, in connection with the reverse recapitalization transaction with Pre-Merger Crescent, we changed our jurisdiction of incorporation from the state of Delaware to the Cayman Islands pursuant to a plan of conversion.
In its own words, from its 10-K, filed Feb 26, 2026.
Crescent Biopharma against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CBIO Crescent Biopharma | Q1 2026 | $1.0M | — | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Crescent Biopharma 10-Q on SEC EDGAR · CIK 1253689 · Pharmaceutical Preparations
More on CBIO
History
Every quarter: Q1 2026 results